Why adhesive polymer technology?

In the same way that surgical staplers revolutionised many surgical procedures in the eighties and nineties, we believe surgically effective adhesive compounds have the capability to drive changes in the foreseeable future.

The following is extracted from the MedMarket Diligence 2009 report into Surgical Sealants, Glues, Wound Closure, Anti-Adhesion, Worldwide:

The use of these biologicals and other product forms, once representing a minor share of wound closure, has now moved into the mainstream, with sealant, closure, hemostasis and combinations of uses by these products eclipsing use by traditional wound closure devices.

A number of market leaders have solidified their positions within the surgical closure and securement markets through successful internal development programs and through technology partnerships with innovative vendors of next generation technologies.

New products appear in surgery very frequently, yet in some ways the basic technological underpinnings remain the same. Wounds are sutured together, blood is transfused, fractures are fixed, joints are replaced. Often surgical rudiments remain the same because of conservatism or the need for clinical evidence before new technologies are introduced. Equally frequently however, techniques endure because the challenge of coming up with something better is too great. Tissuemed’s mission is to use its core capability, focused knowledge and experience in the specific technology of adhesive biomaterials to take a fresh look at what can be achieved. Can “cling-films” be used to support and seal compromised tissues and organs? Can adhesive meshes be used to revolutionise the way hernias are repaired? Can adhesive sheets be used to deliver therapeutics to target sites? Could implants with adhesive coatings be made more functionally effective? We believe these are only a few of the questions that could be asked and furthermore we believe that by working with specialists in each of these fields we can collaborate to develop tomorrow’s standard treatments.